The agreement will allow it to expand the company’s US offering with products that are complementary to Cerament, it states.
The company will start selling and marketing selected Collagen Matrix bone graft substitute products under its own brand name, and through its own US distribution network in Q4 2018.
“Today’s deal with Collagen Matrix is important to our plans to build a larger, faster growing US business under our own control. The Collagen Matrix products can be osteoinductive and osteogenic when combined with bone marrow aspirate making them complementary to CERAMENT BVF, which is osteoconductive. We intend to launch these products under our own brand name later this year giving us a suite of products that will allow us to meet more of the bone graft substitute needs of the orthopedic surgeon. Establishing a broader portfolio of bone graft substitute technologies will also significantly improve our competitive position with payors including GPO/IDN’s (Group Purchasing Organization/Integrated Delivery Network), and help our new distribution channel to be more competitive,” said Emil Billbäck, CEO of Bonesupport.
Collagen Matrix products, when combined with autogenous bone marrow, are both osteoinductive and osteogenic. They are used to f ill bony voids or gaps of the skeletal system caused by surgery or traumatic injury.
Recently, Bonesupport also announced that it will create its own US commerical platform.